显示样式:     当前期刊: Nature Reviews Cardiology    加入关注    导出
我的关注
我的收藏
您暂时未登录!
登录
  • Surgery: Circadian rhythms influence surgical outcomes
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-11-16
    Gregory B. Lim

    Surgery: Circadian rhythms influence surgical outcomes Surgery: Circadian rhythms influence surgical outcomes, Published online: 16 November 2017; doi:10.1038/nrcardio.2017.186

    更新日期:2017-11-16
  • Hypertension: Promising mitochondria-targeting drug for PAH
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-11-16
    Irene Fernández-Ruiz

    Hypertension: Promising mitochondria-targeting drug for PAH Hypertension: Promising mitochondria-targeting drug for PAH, Published online: 16 November 2017; doi:10.1038/nrcardio.2017.188

    更新日期:2017-11-16
  • The NLRP3 inflammasome in acute myocardial infarction
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-11-16
    Stefano Toldo, Antonio Abbate

    The NLRP3 inflammasome in acute myocardial infarction The NLRP3 inflammasome in acute myocardial infarction, Published online: 16 November 2017; doi:10.1038/nrcardio.2017.161 NatureArticleSnippet(type=short-summary, markup= Ischaemic injury during an acute myocardial infarction (AMI) event is followed by an intense inflammatory response that occurs after reperfusion. The inflammasome is a protein complex involved in the regulation of this inflammatory response. In this Review, Toldo and Abbate summarize evidence supporting the therapeutic value of inflammasome-targeted strategies in the context of AMI. , isJats=true)

    更新日期:2017-11-16
  • Next-generation pacemakers: from small devices to biological pacemakers
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-11-16
    Eugenio Cingolani, Joshua I. Goldhaber, Eduardo Marbán

    Next-generation pacemakers: from small devices to biological pacemakers Next-generation pacemakers: from small devices to biological pacemakers, Published online: 16 November 2017; doi:10.1038/nrcardio.2017.165 NatureArticleSnippet(type=short-summary, markup= Conduction system disorders lead to slow heart rates that are insufficient to support the circulation, necessitating implantation of electronic pacemakers. Current pacemakers, although effective, have limitations including lead malfunction, lack of autonomic responsiveness, and device-related infections. In this Review, Marbán and colleagues discuss next-generation electronic devices designed to address current limitations, as well as biological pacemakers as alternatives to implantable hardware. , isJats=true)

    更新日期:2017-11-16
  • Surgery: Circadian rhythms influence surgical outcomes
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-11-16
    Gregory B. Lim

    Surgery: Circadian rhythms influence surgical outcomes Surgery: Circadian rhythms influence surgical outcomes, Published online: 16 November 2017; doi:10.1038/nrcardio.2017.186

    更新日期:2017-11-16
  • Hypertension: Promising mitochondria-targeting drug for PAH
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-11-16
    Irene Fernández-Ruiz

    Hypertension: Promising mitochondria-targeting drug for PAH Hypertension: Promising mitochondria-targeting drug for PAH, Published online: 16 November 2017; doi:10.1038/nrcardio.2017.188

    更新日期:2017-11-16
  • The NLRP3 inflammasome in acute myocardial infarction
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-11-16
    Stefano Toldo, Antonio Abbate

    The NLRP3 inflammasome in acute myocardial infarction The NLRP3 inflammasome in acute myocardial infarction, Published online: 16 November 2017; doi:10.1038/nrcardio.2017.161 NatureArticleSnippet(type=short-summary, markup= Ischaemic injury during an acute myocardial infarction (AMI) event is followed by an intense inflammatory response that occurs after reperfusion. The inflammasome is a protein complex involved in the regulation of this inflammatory response. In this Review, Toldo and Abbate summarize evidence supporting the therapeutic value of inflammasome-targeted strategies in the context of AMI. , isJats=true)

    更新日期:2017-11-16
  • Next-generation pacemakers: from small devices to biological pacemakers
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-11-16
    Eugenio Cingolani, Joshua I. Goldhaber, Eduardo Marbán

    Next-generation pacemakers: from small devices to biological pacemakers Next-generation pacemakers: from small devices to biological pacemakers, Published online: 16 November 2017; doi:10.1038/nrcardio.2017.165 NatureArticleSnippet(type=short-summary, markup= Conduction system disorders lead to slow heart rates that are insufficient to support the circulation, necessitating implantation of electronic pacemakers. Current pacemakers, although effective, have limitations including lead malfunction, lack of autonomic responsiveness, and device-related infections. In this Review, Marbán and colleagues discuss next-generation electronic devices designed to address current limitations, as well as biological pacemakers as alternatives to implantable hardware. , isJats=true)

    更新日期:2017-11-16
  • Anticoagulation therapy: Oral anticoagulants reduce dementia risk in patients with AF
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-11-09
    Karina Huynh

    Anticoagulation therapy: Oral anticoagulants reduce dementia risk in patients with AFAnticoagulation therapy: Oral anticoagulants reduce dementia risk in patients with AF, Published online: 09 November 2017; doi:10.1038/nrcardio.2017.185

    更新日期:2017-11-10
  • Anticoagulation therapy: Oral anticoagulants reduce dementia risk in patients with AF
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-11-09
    Karina Huynh

    Anticoagulation therapy: Oral anticoagulants reduce dementia risk in patients with AFAnticoagulation therapy: Oral anticoagulants reduce dementia risk in patients with AF, Published online: 09 November 2017; doi:10.1038/nrcardio.2017.185

    更新日期:2017-11-10
  • Atherosclerosis: Association between the gut microbiome and atherosclerosis
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-11-03
    William T. Barrington, Aldons J. Lusis

    Atherosclerosis: Association between the gut microbiome and atherosclerosis Atherosclerosis: Association between the gut microbiome and atherosclerosis, Published online: 03 November 2017; doi:10.1038/nrcardio.2017.169 NatureArticleSnippet(type=standfirst, markup= The gut microbiota has been associated with many different disorders, including cardiovascular diseases. A new study by Jie and colleagues is the first large case–control study to examine directly the enrichment of certain communities of gut bacteria in patients with atherosclerotic cardiovascular disease compared with control individuals. , isJats=true)

    更新日期:2017-11-03
  • Atherosclerosis: Association between the gut microbiome and atherosclerosis
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-11-03
    William T. Barrington, Aldons J. Lusis

    Atherosclerosis: Association between the gut microbiome and atherosclerosis Atherosclerosis: Association between the gut microbiome and atherosclerosis, Published online: 03 November 2017; doi:10.1038/nrcardio.2017.169 NatureArticleSnippet(type=standfirst, markup= The gut microbiota has been associated with many different disorders, including cardiovascular diseases. A new study by Jie and colleagues is the first large case–control study to examine directly the enrichment of certain communities of gut bacteria in patients with atherosclerotic cardiovascular disease compared with control individuals. , isJats=true)

    更新日期:2017-11-03
  • Acute coronary syndromes: Myocardial salvage with HDL infusion after infarction
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-10-26
    Gregory B. Lim

    Acute coronary syndromes: Myocardial salvage with HDL infusion after infarction Nature Reviews Cardiology, Published online: 26 October 2017; doi:10.1038/nrcardio.2017.168

    更新日期:2017-10-30
  • Anticoagulant therapy: Interaction between NOACs and other drugs increases bleeding risk
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-10-26
    Gregory B. Lim

    Anticoagulant therapy: Interaction between NOACs and other drugs increases bleeding risk Nature Reviews Cardiology, Published online: 26 October 2017; doi:10.1038/nrcardio.2017.167

    更新日期:2017-10-30
  • Acute coronary syndromes: Myocardial salvage with HDL infusion after infarction
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-10-26
    Gregory B. Lim

    Acute coronary syndromes: Myocardial salvage with HDL infusion after infarction Nature Reviews Cardiology, Published online: 26 October 2017; doi:10.1038/nrcardio.2017.168

    更新日期:2017-10-30
  • Anticoagulant therapy: Interaction between NOACs and other drugs increases bleeding risk
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-10-26
    Gregory B. Lim

    Anticoagulant therapy: Interaction between NOACs and other drugs increases bleeding risk Nature Reviews Cardiology, Published online: 26 October 2017; doi:10.1038/nrcardio.2017.167

    更新日期:2017-10-30
  • Atherosclerosis: Mitochondrial fission is crucial for efferocytosis
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-10-20
    Irene Fernanández-Ruiz

    Atherosclerosis: Mitochondrial fission is crucial for efferocytosis Nature Reviews Cardiology, Published online: 20 October 2017; doi:10.1038/nrcardio.2017.162

    更新日期:2017-10-30
  • Nutrition: Start your day with a high-energy breakfast
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-10-20
    Irene Fernanández-Ruiz

    Nutrition: Start your day with a high-energy breakfast Nature Reviews Cardiology, Published online: 20 October 2017; doi:10.1038/nrcardio.2017.164

    更新日期:2017-10-30
  • Basic research: Inhibition of Hippo pathway signalling reverses systolic heart failure
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-10-20
    Karina Huynh

    Basic research: Inhibition of Hippo pathway signalling reverses systolic heart failure Nature Reviews Cardiology, Published online: 20 October 2017; doi:10.1038/nrcardio.2017.166

    更新日期:2017-10-30
  • Heart in space: effect of the extraterrestrial environment on the cardiovascular system
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-10-20
    Richard L. Hughson, Alexander Helm, Marco Durante

    National space agencies and private corporations aim at an extended presence of humans in space in the medium to long term. Together with currently suboptimal technology, microgravity and cosmic rays raise health concerns about deep-space exploration missions. Both of these physical factors affect the cardiovascular system, whose gravity-dependence is pronounced. Heart and vascular function are, therefore, susceptible to substantial changes in weightlessness. The altered cardiovascular function in space causes physiological problems in the postflight period. A compromised cardiovascular system can be excessively vulnerable to space radiation, synergistically resulting in increased damage. The space radiation dose is significantly lower than in patients undergoing radiotherapy, in whom cardiac damage is well-documented following cancer therapy in the thoracic region. Nevertheless, epidemiological findings suggest an increased risk of late cardiovascular disease even with low doses of radiation. Moreover, the peculiar biological effectiveness of heavy ions in cosmic rays might increase this risk substantially. However, whether radiation-induced cardiovascular effects have a threshold at low doses is still unclear. The main countermeasures to mitigate the effect of the space environment on cardiac function are physical exercise, antioxidants, nutraceuticals, and radiation shielding.

    更新日期:2017-10-30
  • Prevention: Non-recreational physical activity reduces CVD risk
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-10-20
    Irene Fernanández-Ruiz

    Prevention: Non-recreational physical activity reduces CVD risk Nature Reviews Cardiology, Published online: 20 October 2017; doi:10.1038/nrcardio.2017.163

    更新日期:2017-10-30
  • Gastrointestinal sodium absorption, microbiome, and hypertension
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-11-01
    Ricardo S. Mishima, Adrian D. Elliott, Prashanthan Sanders, Dominik Linz

    Gastrointestinal sodium absorption, microbiome, and hypertension Nature Reviews Cardiology, Published online: 13 October 2017; doi:10.1038/nrcardio.2017.159

    更新日期:2017-10-30
  • Atherosclerosis: Mitochondrial fission is crucial for efferocytosis
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-10-20
    Irene Fernanández-Ruiz

    Atherosclerosis: Mitochondrial fission is crucial for efferocytosis Nature Reviews Cardiology, Published online: 20 October 2017; doi:10.1038/nrcardio.2017.162

    更新日期:2017-10-21
  • Nutrition: Start your day with a high-energy breakfast
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-10-20
    Irene Fernanández-Ruiz

    Nutrition: Start your day with a high-energy breakfast Nature Reviews Cardiology, Published online: 20 October 2017; doi:10.1038/nrcardio.2017.164

    更新日期:2017-10-21
  • Basic research: Inhibition of Hippo pathway signalling reverses systolic heart failure
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-10-20
    Karina Huynh

    Basic research: Inhibition of Hippo pathway signalling reverses systolic heart failure Nature Reviews Cardiology, Published online: 20 October 2017; doi:10.1038/nrcardio.2017.166

    更新日期:2017-10-21
  • Heart in space: effect of the extraterrestrial environment on the cardiovascular system
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-10-20
    Richard L. Hughson, Alexander Helm, Marco Durante

    Heart in space: effect of the extraterrestrial environment on the cardiovascular system Nature Reviews Cardiology, Published online: 20 October 2017; doi:10.1038/nrcardio.2017.157 The effects of microgravity and cosmic rays on the cardiovascular system are major health concerns for astronauts in space. In this Review, Hughson and colleagues summarize the current evidence on risk estimation and dysfunction of the cardiovascular system in space, and discuss potential countermeasures, including physical exercise, antioxidants, nutraceuticals, and radiation shielding.

    更新日期:2017-10-21
  • Prevention: Non-recreational physical activity reduces CVD risk
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-10-20
    Irene Fernanández-Ruiz

    Prevention: Non-recreational physical activity reduces CVD risk Nature Reviews Cardiology, Published online: 20 October 2017; doi:10.1038/nrcardio.2017.163

    更新日期:2017-10-21
  • Gastrointestinal sodium absorption, microbiome, and hypertension
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 
    Ricardo S. Mishima, Adrian D. Elliott, Prashanthan Sanders, Dominik Linz

    Gastrointestinal sodium absorption, microbiome, and hypertension Nature Reviews Cardiology, Published online: 13 October 2017; doi:10.1038/nrcardio.2017.159

    更新日期:2017-10-13
  • Epidemiology of cardiovascular disease in young individuals
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 
    Charlotte Andersson, Ramachandran S. Vasan

    In the past 2 decades, a high prevalence of risk factors for cardiovascular disease, such as obesity, physical inactivity, and poor diet, has been observed among young individuals living in developed countries. The rate of substance abuse (opioids, cocaine, electronic cigarettes, and anabolic steroids) is also increasing among young adults, whereas cigarette smoking might be declining. Among younger individuals (aged 18–50 years), the incidence of cardiovascular diseases over the same time period has either been steady or has increased, in contrast to the trend towards a lower incidence of cardiovascular disease in adults aged >50 years. Current observations might, therefore, be used to forecast a potential epidemic of cardiovascular disease in the near future as the younger segment of the population ages. In this Review, we discuss the burden of risk factors for ischaemic heart disease, heart failure, atrial fibrillation, and sudden cardiac death among young adults aged 18–45 years. Furthermore, we discuss the prevalence, incidence, and temporal trends of various cardiovascular diseases among this young segment of the population.

    更新日期:2017-10-12
  • Pharmacotherapy: Aspirin discontinuation increases risk of cardiovascular events
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 
    Karina Huynh

    Pharmacotherapy: Aspirin discontinuation increases risk of cardiovascular events Nature Reviews Cardiology, Published online: 12 October 2017; doi:10.1038/nrcardio.2017.160

    更新日期:2017-10-12
  • Arterial stiffness as a risk factor for clinical hypertension
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 
    Michel E. Safar

    In patients with uncomplicated essential hypertension, cardiac output remains within normal ranges and intravascular volume is normal or low, assuming the presence of a sufficient Windkessel effect and usual resistance and compliance calculations. However, mean circulatory pressure is elevated in these patients. In addition, vascular resistance is augmented, and most importantly, the viscoelasticity of the cardiovascular system is substantially impaired. Such considerations are essential to understanding the mechanisms behind carotid–femoral arterial stiffness, a major risk factor in individuals with hypertension. Arterial stiffness, measured from pulse wave velocity, is substantially increased in hypertension even independently of blood pressure levels. Structural vascular changes and endothelial dysfunction are consistently associated with vessel impairments in animal models of hypertension. Increased arterial stiffness has a major effect on pulse pressure (the difference between systolic and diastolic blood pressure), wave reflections, kidney function, and above all, cardiovascular risk. This increased cardiovascular risk is particularly deleterious in patients with hypertension and/or type 2 diabetes mellitus, who are at risk of both renal and cardiovascular events. In this Review, we discuss the importance of arterial stiffness in the diagnosis and management of hypertension and the need for new approaches for the treatment of hypertension in patients with or without diabetes and/or renal impairment.

    更新日期:2017-10-12
  • Dyslipidaemia: Revealing the effect of CETP inhibition in cardiovascular disease
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 
    Michael V. Holmes, George Davey Smith

    Dyslipidaemia: Revealing the effect of CETP inhibition in cardiovascular disease Nature Reviews Cardiology, Published online: 5 October 2017; doi:10.1038/nrcardio.2017.156 Initial randomized trials of cholesteryl ester transfer protein (CETP) inhibitors were terminated early owing to adverse effects or futility. The REVEAL trial now shows the benefit of CETP inhibition in coronary heart disease. Despite raising HDL-cholesterol levels, the cardiovascular effect of CETP inhibitors is probably due to lowering of non-HDL-cholesterol levels.

    更新日期:2017-10-11
  • Imaging: Mitochondria shine light on heart function
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 
    Irene Fernández-Ruiz

    Imaging: Mitochondria shine light on heart function Nature Reviews Cardiology, Published online: 5 October 2017; doi:10.1038/nrcardio.2017.158

    更新日期:2017-10-11
  • The ABC pathway: an integrated approach to improve AF management
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 
    Gregory Y. H. Lip

    The ABC pathway: an integrated approach to improve AF management Nature Reviews Cardiology, Published online: 29 September 2017; doi:10.1038/nrcardio.2017.153 The Atrial fibrillation Better Care (ABC) pathway for integrated management provides a simple strategy (Avoid stroke, Better symptom management, and Cardiovascular and comorbidity risk reduction) that helps to improve awareness and detection, and reminds clinicians of the simple decision-making steps for management of patients with atrial fibrillation in a holistic approach.

    更新日期:2017-10-11
  • Cardiovascular disease in the Eastern Mediterranean region: epidemiology and risk factor burden
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 
    Karam Turk-Adawi, Nizal Sarrafzadegan, Ibtihal Fadhil, Kathryn Taubert, Masoumeh Sadeghi, Nanette K. Wenger, Nigel S. Tan, Sherry L. Grace

    The Eastern Mediterranean region (EMR) comprises 22 countries or territories spanning from Morocco in the west to Pakistan in the east, and contains a population of almost 600 million people. Like many other developing regions, the burden of disease in the EMR has shifted in the past 30 years from primarily communicable diseases to noncommunicable diseases such as cardiovascular disease (CVD). Cardiovascular mortality in the EMR, mostly attributable to ischaemic heart disease, is expected to increase more dramatically in the next decade than in any other region except Africa. The most prominent CVD risk factors in this region include tobacco consumption, physical inactivity, depression, obesity, hypertension, and diabetes mellitus. Many individuals living in the EMR are unaware of their risk factor status, and even if treated, these risk factors are often poorly controlled. Furthermore, infrequent use of emergency medical services, delays in access to care, and lack of access to cardiac catheterization affects the timely diagnosis of CVD. Treatment of CVD is also suboptimal in this region, consisting primarily of thrombolysis, with insufficient provision of timely revascularization. In this Review, we summarize what is known about CVD burden, risk factors, and treatment strategies for individuals living in the EMR. This information will hopefully aid decision-makers when devising strategies on how to improve CVD prevention and management in this region.

    更新日期:2017-09-21
  • Reverse remodelling and myocardial recovery in heart failure
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 
    Gene H. Kim, Nir Uriel, Daniel Burkhoff

    Advances in medical and device therapies have demonstrated the capacity of the heart to reverse the failing phenotype. The development of normative changes to ventricular size and function led to the concept of reverse remodelling. Among heart failure therapies, durable mechanical circulatory support is most consistently associated with the largest degree of reverse remodelling. Accordingly, research to analyse human tissue after a period of mechanical circulatory support continues to yield a wealth of information. In this Review, we summarize the latest findings on reverse remodelling and myocardial recovery. Accumulating evidence shows that the molecular changes associated with heart failure, in particular in the transcriptome, metabalome, and extracellular matrix, persist in the reverse-remodelled myocardium despite apparent normalization of macrolevel properties. Therefore, reverse remodelling should be distinguished from true myocardial recovery, in which a failing heart regains both normal function and molecular makeup. These findings have implications for future research to develop therapies to repair fully the failing myocardium. Meanwhile, recognition by society guidelines of this new clinical phenotype, which is coming to be known as a state of heart failure remission, underscores the need to accurately define and identify reverse modelled myocardium for the establishment of appropriate therapies.

    更新日期:2017-09-21
  • Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-09-14
    Pal Pacher, Sabine Steffens, György Haskó, Thomas H. Schindler, George Kunos

    Dysregulation of the endogenous lipid mediators endocannabinoids and their G-protein-coupled cannabinoid receptors 1 and 2 (CB1R and CB2R) has been implicated in a variety of cardiovascular pathologies. Activation of CB1R facilitates the development of cardiometabolic disease, whereas activation of CB2R (expressed primarily in immune cells) exerts anti-inflammatory effects. The psychoactive constituent of marijuana, Δ9-tetrahydrocannabinol (THC), is an agonist of both CB1R and CB2R, and exerts its psychoactive and adverse cardiovascular effects through the activation of CB1R in the central nervous and cardiovascular systems. The past decade has seen a nearly tenfold increase in the THC content of marijuana as well as the increased availability of highly potent synthetic cannabinoids for recreational use. These changes have been accompanied by the emergence of serious adverse cardiovascular events, including myocardial infarction, cardiomyopathy, arrhythmias, stroke, and cardiac arrest. In this Review, we summarize the role of the endocannabinoid system in cardiovascular disease, and critically discuss the cardiovascular consequences of marijuana and synthetic cannabinoid use. With the legalization of marijuana for medicinal purposes and/or recreational use in many countries, physicians should be alert to the possibility that the use of marijuana or its potent synthetic analogues might be the underlying cause of severe cardiovascular events and pathologies.

    更新日期:2017-09-15
  • Anticoagulation therapy: Bivalirudin not superior to heparin in PCI
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 
    Gregory B. Lim

    Anticoagulation therapy: Bivalirudin not superior to heparin in PCI Nature Reviews Cardiology, Published online: 14 September 2017; doi:10.1038/nrcardio.2017.142

    更新日期:2017-09-14
  • Vascular disease: Benefits of population screening for vascular risk
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 
    Gregory B. Lim

    Vascular disease: Benefits of population screening for vascular risk Nature Reviews Cardiology, Published online: 14 September 2017; doi:10.1038/nrcardio.2017.144

    更新日期:2017-09-14
  • Coronary artery disease: Coronary artery calcium testing
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 
    Karina Huynh

    Coronary artery disease: Coronary artery calcium testing Nature Reviews Cardiology, Published online: 14 September 2017; doi:10.1038/nrcardio.2017.146

    更新日期:2017-09-14
  • Hypertension: Ibuprofen increases blood pressure in patients with arthritis
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 
    Irene Fernández-Ruiz

    Hypertension: Ibuprofen increases blood pressure in patients with arthritis Nature Reviews Cardiology, Published online: 14 September 2017; doi:10.1038/nrcardio.2017.150

    更新日期:2017-09-14
  • Bivalirudin for patients with STEMI at high risk of bleeding undergoing PPCI
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 
    Lu Hu, Kai Guo, Zhigang Guo

    Bivalirudin for patients with STEMI at high risk of bleeding undergoing PPCI Nature Reviews Cardiology, Published online: 14 September 2017; doi:10.1038/nrcardio.2017.141

    更新日期:2017-09-14
  • Antithrombotic therapy: COMPASS points to low-dose rivaroxaban and aspirin for secondary prevention
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 
    Gregory B. Lim

    Antithrombotic therapy: COMPASS points to low-dose rivaroxaban and aspirin for secondary prevention Nature Reviews Cardiology, Published online: 14 September 2017; doi:10.1038/nrcardio.2017.148

    更新日期:2017-09-14
  • Inflammation: Targeting inflammatory pathways to treat atherosclerosis and cancer
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 
    Karina Huynh

    Inflammation: Targeting inflammatory pathways to treat atherosclerosis and cancer Nature Reviews Cardiology, Published online: 14 September 2017; doi:10.1038/nrcardio.2017.152

    更新日期:2017-09-14
  • Acute coronary syndromes: Supplemental oxygen in myocardial infarction
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 
    Gregory B. Lim

    Acute coronary syndromes: Supplemental oxygen in myocardial infarction Nature Reviews Cardiology, Published online: 14 September 2017; doi:10.1038/nrcardio.2017.143

    更新日期:2017-09-14
  • Genetics: Human genome editing in heart disease
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-08-17
    Gregory B. Lim

    Human germline genome editing with CRISPR–Cas9 can be used with high efficiency, accuracy, and safety to correct a heterozygous, autosomal dominant mutation in MYBPC3 associated with hypertrophic cardiomyopathy, according to a new study in Nature.CRISPR–Cas9 is a versatile tool for recognizing a

    更新日期:2017-09-14
  • Cardioprotection: Anti-ageing effects of cardiosphere-derived cells
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-08-31
    Irene Fernández-Ruiz

    Cardiosphere-derived cells (CDCs) from young animals can rejuvenate old animals. New research shows that intracardiac injection of neonatal rat CDCs in old rats improves heart function (reducing cardiac stiffness, hypertrophy, fibrosis, and diastolic dysfunction), increases exercise capacity by ∼20%, and improves the levels of systemic

    更新日期:2017-09-14
  • Surgery: On-pump superior to off-pump CABG surgery
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-08-31
    Irene Fernández-Ruiz

    A follow-up study including 2,203 patients from a US-based randomized trial shows that CABG surgery performed without cardiopulmonary bypass (off pump) is associated with lower rates of 5-year survival and event-free survival than CABG surgery with cardiopulmonary bypass (on pump). In all 5-year clinical outcomes

    更新日期:2017-09-14
  • Dyslipidaemia: No effect of PCSK9 inhibitors on cognitive function
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-08-31
    Irene Fernández-Ruiz

    Use of PCSK9 inhibitors is not associated with adverse cognitive effects, even among patients who attain very low levels of LDL cholesterol, according to a study in a subgroup of 1,204 patients from the FOURIER trial, a randomized trial of the PCSK9 inhibitor evolocumab added

    更新日期:2017-09-14
  • Basic research: Minimally invasive delivery of engineered cardiac patches for heart repair
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-08-31
    Karina Huynh

    A novel elastic and microfabricated scaffold created using a biodegradable polymer has been developed to produce cardiac patches for delivery via injection into the heart. These patches significantly improved cardiac function in a rat model of myocardial infarction compared with untreated controls, according to a

    更新日期:2017-09-14
  • Cardiac regeneration: Cardiomyocyte proliferation: a variable genetic trait?
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-08-24
    Gregory B. Lim

    “Heart injury does not inexorably lead to a permanent loss of myocardium and diminished function,” conclude the researchers in a new study published in Nature Genetics. Their findings indicate that mononuclear diploid cardiomyocytes (MNDCMs) might have the capacity to proliferate, and that the MNDCM

    更新日期:2017-09-14
  • Antiplatelet therapy: Aspirin in the elderly — tailored approaches ahead?
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-08-10
    Victor Serebruany, Elena Golukhova

    The benefits of aspirin in protecting against thrombotic occlusions are well-established. However, aspirin use has also been linked to increased gastrointestinal and fatal bleeding in elderly patients. Safer preventive approaches should be considered in the elderly population, including reductions in aspirin dose, alternative daily regimens, and individualized treatment strategies.

    更新日期:2017-09-14
  • Genetics: From non-coding risk variant to biological mechanism in CAD
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-08-10
    Linda Koch

    Analyses of the genetic architecture of complex diseases such as coronary artery disease (CAD) have revealed that most genetic variants are located in non-coding regions of the genome. As regulatory variants can act over long genomic distances, the causal gene and specific mechanism through which

    更新日期:2017-09-14
  • Mendelian randomization in cardiometabolic disease: challenges in evaluating causality
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-06-01
    Michael V. Holmes, Mika Ala-Korpela, George Davey Smith

    Mendelian randomization (MR) is a burgeoning field that involves the use of genetic variants to assess causal relationships between exposures and outcomes. MR studies can be straightforward; for example, genetic variants within or near the encoding locus that is associated with protein concentrations can help to assess their causal role in disease. However, a more complex relationship between the genetic variants and an exposure can make findings from MR more difficult to interpret. In this Review, we describe some of these challenges in interpreting MR analyses, including those from studies using genetic variants to assess causality of multiple traits (such as branched-chain amino acids and risk of diabetes mellitus); studies describing pleiotropic variants (for example, C-reactive protein and its contribution to coronary heart disease); and those investigating variants that disrupt normal function of an exposure (for example, HDL cholesterol or IL-6 and coronary heart disease). Furthermore, MR studies on variants that encode enzymes responsible for the metabolism of an exposure (such as alcohol) are discussed, in addition to those assessing the effects of variants on time-dependent exposures (extracellular superoxide dismutase), cumulative exposures (LDL cholesterol), and overlapping exposures (triglycerides and non-HDL cholesterol). We elaborate on the molecular features of each relationship, and provide explanations for the likely causal associations. In doing so, we hope to contribute towards more reliable evaluations of MR findings.

    更新日期:2017-09-14
  • Basic research: Standardizing animal atherosclerosis studies to improve reproducibility
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-09-07
    Oliver Soehnlein, Carlos Silvestre-Roig

    Contradictory results in animal atherosclerosis studies might partly explain limited translational efficacy, and also undermine the confidence of funding agencies, politicians, and the public in scientists and their research. A new guideline paper provides recommendations aimed at standardization of animal atherosclerosis studies to improve the reproducibility of this research.

    更新日期:2017-09-14
  • Imaging: Perivascular fat — an unheralded informant of coronary inflammation
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-08-24
    Marc R. Dweck, Zahi A. Fayad

    A novel image-analysis method using standard CT imaging demonstrates that changes in the CT signal of coronary perivascular adipose tissue are associated with the degree of inflammation in adjacent coronary plaques. This exciting development might become a useful adjuvant clinical tool, although further validation and prospective outcome studies are required.

    更新日期:2017-09-14
  • Epidemiology of heart failure with preserved ejection fraction
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-05-11
    Shannon M. Dunlay, Véronique L. Roger, Margaret M. Redfield

    Heart failure (HF) with preserved ejection fraction (HFpEF) is a clinical syndrome associated with poor quality of life, substantial health-care resource utilization, and premature mortality. We summarize the current knowledge regarding the epidemiology of HFpEF with a focus on community-based studies relevant to quantifying the population burden of HFpEF. Current data regarding the prevalence and incidence of HFpEF in the community as well as associated conditions and risk factors, risk of morbidity and mortality after diagnosis, and quality of life are presented. In the community, approximately 50% of patients with HF have HFpEF. Although the age-specific incidence of HF is decreasing, this trend is less dramatic for HFpEF than for HF with reduced ejection fraction (HFrEF). The risk of HFpEF increases sharply with age, but hypertension, obesity, and coronary artery disease are additional risk factors. After adjusting for age and other risk factors, the risk of HFpEF is fairly similar in men and women, whereas the risk of HFrEF is much lower in women. Multimorbidity is common in both types of HF, but slightly more severe in HFpEF. A majority of deaths in patients with HFpEF are cardiovascular, but the proportion of noncardiovascular deaths is higher in HFpEF than HFrEF.

    更新日期:2017-09-14
  • Epidemiology and treatment of pulmonary arterial hypertension
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-06-08
    Edmund M. T. Lau, Eleni Giannoulatou, David S. Celermajer, Marc Humbert

    In the past 2 decades, major changes have occurred in the epidemiological and treatment landscape of pulmonary arterial hypertension (PAH). Previously regarded as a disease of the young and middle-aged, contemporary registries from the Western world have demonstrated an increase in the age of patients with PAH, many of whom are elderly with multiple comorbidities. Another important observation is the improvement in survival of patients with PAH in the modern treatment era compared with historical cohorts, before the availability of advanced therapy. The management of PAH has also become more complex, and numerous drugs are now approved that target the endothelin 1, nitric oxide, and prostacyclin pathways. Combining drugs from different classes is now considered the standard of care and has been demonstrated to improve outcomes. Furthermore, the current treatment paradigm is the early use of combination therapy, often at the time of diagnosis, particularly in patients with severe disease. This Review provides a comprehensive update on the epidemiology and pharmacotherapy of PAH.

    更新日期:2017-09-14
  • Matching patients with the ever-expanding range of TAVI devices
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-07-06
    Brandon M. Jones, Amar Krishnaswamy, E. Murat Tuzcu, Stephanie Mick, Wael A. Jaber, Lars G. Svensson, Samir R. Kapadia

    Transcatheter aortic valve implantation (TAVI) has become a widely accepted strategy for the treatment of aortic stenosis in patients at intermediate, high, or prohibitive surgical risk. After >1 decade of innovation and clinical trial experience, the available technology for TAVI has grown enormously, and now includes a myriad of vascular access approaches and innovative valve designs. As a result, the range of patients who can benefit from these advances continues to grow rapidly. Furthermore, given the improved safety profile and clinical success of current-generation devices in randomized trials, the use of TAVI among even low-risk populations is justified in current trials. With the rapid dissemination and expansion of this technology, operators need to have a comprehensive understanding of how to select the appropriate procedural approach for each individual patient. In this Review, we detail the current evidence for TAVI among different patient populations, discuss the different vascular access approaches currently in use, and explore differences in design features among currently available and investigational valve systems. Furthermore, we provide an overview of important considerations for special patient populations, such as those with existing mitral prostheses, bicuspid aortic stenosis, isolated aortic regurgitation, or severe left ventricular outflow tract calcification.

    更新日期:2017-09-14
  • Bivalirudin for patients with STEMI at high risk of bleeding undergoing PPCI
    Nat. Rev. Cardiol. (IF 14.299) Pub Date : 2017-09-14
    Lu Hu, Kai Guo, Zhigang Guo

    We read the Review by Franchi et al. (Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nat. Rev. Cardiol.14, 361–379; 2017) with great interest. We wish to discuss the role of bivalirudin for patients with ST-segment elevation myocardial

    更新日期:2017-09-14
Some contents have been Reproduced with permission of the American Chemical Society.
Some contents have been Reproduced by permission of The Royal Society of Chemistry.
化学 · 材料 期刊列表